Group 1: Investor Relations Activity Overview - The company participated in the "2024 Jiangxi Listed Companies Investor Reception Day" on May 17, 2024, via an online platform [2] - The event was organized by the Jiangxi Provincial Association of Listed Companies and Shenzhen Panorama Network Co., Ltd. [2] - Key attendees included Chairman Zhang Aijiang and CFO Cheng Shuping [2] Group 2: Financial Performance Highlights - As of the end of 2023, the company's total assets were approximately 522 million CNY, representing a 47.49% increase from the previous year [4] - Total liabilities amounted to 48 million CNY, showing a 32.28% decrease compared to the previous year [4] - The asset-liability ratio improved from 14.31% to 4.89%, indicating a healthier financial position [4] Group 3: Future Business Strategy - The company aims to expand its business from raw materials to integrated production, focusing on domestic formulation strategies [5] - Key products include Vitamin C chewable tablets and other proprietary formulations, which accounted for approximately 49% of revenue in 2023 [5] - The company is transitioning from being primarily a raw material pharmaceutical enterprise to a comprehensive brand pharmaceutical company [5]
新赣江(873167) - 投资者关系活动记录表